Common-Size Income Statement
Quarterly Data
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Pfizer Inc., common-size consolidated income statement (quarterly data)
Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).
The financial data reveals several notable trends and fluctuations over the reported periods. Revenue composition shows product revenues ranging mostly in the low to mid 80% range, demonstrating a generally dominant contribution, while alliance and royalty revenues together make up the complementary share with some variability but stable overall presence.
Cost of sales as a percentage of revenues experiences significant volatility, with notable spikes reaching nearly -69% in one period and fluctuating considerably across quarters. Despite these fluctuations, gross profit margins remain positive but variable, reflecting the impact of changing cost structures; margins range broadly from approximately 31% to over 80% across the timeline, indicating periods of compression and expansion in profitability at the gross level.
Operating expenses including selling, informational and administrative costs tend to vary between roughly -10% and -32%, showing periods of cost efficiency and others of increased spending or potentially restructuring activities. Research and development expenses, another major cost component, generally range between approximately -8% and -29%, indicating a sustained but varying investment in current and future product development.
Amortization of intangible assets remains relatively stable as a small but consistent expense, generally between -4% and -9%. Restructuring charges and acquisition-related costs display occasional spikes, such as a sharp increase to nearly -18% in one reporting period, suggestive of significant one-time charges or strategic realignments during certain quarters.
Operating income shows considerable volatility including some negative swings, decreasing notably in a few quarters but generally recovering later on, with percentages fluctuating from nearly -30% to more than 44%. Income from continuing operations before taxes and income taxes themselves follow similar patterns with variability but overall positive contribution in most quarters.
Net income attributable to common shareholders fluctuates widely, with several periods of positive returns exceeding 30%, contrasted by some quarters exhibiting negative outcomes, indicating earnings sensitivity to underlying cost and revenue changes as well as tax and other income variations.
Discontinued operations and net income attributable to noncontrolling interests are relatively minor in proportion and show no consistent directional trend. Overall, the data illustrates that profitability margins and expense management have encountered periods of strain and recovery, reflecting dynamic market conditions and internal operational adjustments over the reported periods.